SCHEMBL3390883

SCHEMBL3390883

CC(=O)[C@@H](O)[C@@H](O)[C@H](O)CO

nearest known ligand 0.52

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.52
LMNA P02545 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
TDP1 Q9NUW8 2/20 0.48
USP2 O75604 1/20 0.43
SLCO1B1 Q9Y6L6 1/20 0.43
KDM4E B2RXH2 2/20 0.41
OR51E2 Q9H255 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CYP2C9 P11712 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL539547 1.00 PDE4A (0.52) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL3394266 1.00 PDE4A (0.52) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL2621334 1.00 PDE4A (0.52) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL183857 1.00 PDE4A (0.52) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL1521506 1.00 PDE4A (0.52) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL30854359 1.00 PDE4A (0.52) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL30854351 1.00 PDE4A (0.52) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL1671746 1.00 PDE4A (0.52) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL342905 0.92 PDE4A (0.62) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL9961490 0.92 PDE4A (0.62) PDE4ALMNAL3MBTL1TDP1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117903386-A Method for realizing liquid phase polymerization of high-concentration polyhydroxy aldehyde or (and) polyhydroxy ketone through liquid thereof under high-temperature condition 厦门碳控科技投资有限公司 2024-04-19 CN claimed
US-20100105885-A1 DEOXYKETOHEXOSE ISOMERASE AND METHOD FOR PRODUCING DEOXYHEXOSE AND DERIVATIVE THEREOF USING SAME NAT'L UNIVERSITY CORPORATION KAGAWA UNIVERSITY (JP) 2010-04-29 US claimed
EP-2161332-A1 DEOXYKETOHEXOSE ISOMERASE AND METHOD FOR PRODUCING DEOXYKETOHEXOSE AND DERIVATIVE THEREOF USING THE SAME National University Corporation Kagawa University (JP) 2010-03-10 EP claimed
CN-117903386-A Method for realizing liquid phase polymerization of high-concentration polyhydroxy aldehyde or (and) polyhydroxy ketone through liquid thereof under high-temperature condition 厦门碳控科技投资有限公司 2024-04-19 CN disclosed
EP-2161332-B1 DEOXYKETOHEXOSE ISOMERASE AND METHOD FOR PRODUCING DEOXYHEXOSE AND DERIVATIVE THEREOF USING SAME UNIV KAGAWA NAT UNIV CORP (JP) 2015-04-22 EP disclosed
US-8389248-B2 Deoxyketohexose isomerase and method for producing deoxyhexose and derivative thereof using same NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY (JP) 2013-03-05 US disclosed
US-20100105885-A1 DEOXYKETOHEXOSE ISOMERASE AND METHOD FOR PRODUCING DEOXYHEXOSE AND DERIVATIVE THEREOF USING SAME NAT'L UNIVERSITY CORPORATION KAGAWA UNIVERSITY (JP) 2010-04-29 US disclosed
EP-2161332-A1 DEOXYKETOHEXOSE ISOMERASE AND METHOD FOR PRODUCING DEOXYKETOHEXOSE AND DERIVATIVE THEREOF USING THE SAME National University Corporation Kagawa University (JP) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105885-A1 DEOXYKETOHEXOSE ISOMERASE AND METHOD FOR PRODUCING DEOXYHEXOSE AND DERIVATIVE THEREOF USING SAME ALDOA, TALDO1, GPI PDE4A 3583/4885LMNA 4339/4885L3MBTL1 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.